![](/img/cover-not-exists.png)
Bone Marrow (BM) May be More Informative Than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL)
Strati, Paolo, Keating, Michael J., O'Brien, Susan M., Burger, Jan, Ferrajoli, Alessandra, Jain, Nitin, Estrov, Zeev, Jorgensen, Jeffrey, Faderl, Stefan H., Wierda, William G.Volume:
14
Language:
english
Journal:
Clinical Lymphoma Myeloma and Leukemia
DOI:
10.1016/j.clml.2014.06.065
Date:
September, 2014
File:
PDF, 230 KB
english, 2014